Topic: Clinical Trial Results
Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.
Novartis is rolling out head-to-head data for its MS drug in advance of an expected FDA approval next month, but competition will still be tough.
Adding Sanofi's Sarclisa to Amgen's Kyprolis and a steroid cut the risk of disease progression or death in relapsed multiple myeloma.
In a new 18-month analysis, Takeda's dengue vaccine efficacy slipped to 73.3%, down from 80% in an earlier analysis.
Cosentyx has been battling it out with Taltz in psoriatic arthritis. But Lilly’s drug has a big win under its belt that Novartis can't tout.
Novartis is gunning for an OK for Cosentyx in non-radiographic axial spondyloarthritis, and it’s now got one-year data to make its case to the FDA.
Roche’s Tecentriq was the first in its class to break into the bladder cancer arena. And it now could be the first to expand its reach there, too.
Novartis envisioned $5 billion in peak sales for its cardiovascular drug Entresto, but, after a major trial flop, that goal appears out of reach.
Incyte's bone marrow drug Jakafi has been pitching in blockbuster-level sales, and now it has a new approval that could give it another boost.
Join this webinar to learn the five characteristics of a unified platform and how each benefits clinical research both for a single trial and across your suite of research efforts.